Our Team
Our team at AccSalus is comprised of experts from a broad range of interconnected disciplines, combining their expertise in drug discovery, clinical trials and beyond, united in pursuit of a common purpose.
Executive Team
Dr. Auro Nair
Chairman & Chief Executive Officer
Dr. Auro Nair is an accomplished biopharma & life sciences executive with 35+ years of leadership experience. He is currently an Operating Partner at Linden Capital and serves on the Board of Directors of BioIVT, CellBio Scientific, and the Institute of Protein Innovation. Previously, he served as Executive Vice President of The Jackson Laboratory and President of JAX Mice, Clinical & Research Services, where he led transformative growth and international expansion. Prior to that he had held senior commercial & scientific leadership roles at Caliper Life Sciences and Glaxo.
Dr. Yan Yang
Chief Operating Officer
Dr. Yan Yang has 25+ years of experience in translational pharmacology and cross- functional team leadership. His team contributed to the in vivo pharmacology section of 9 approved NDAs/BLAs. He has served as Chief Scientific Officer at several privately held biotech companies.
Dr. Gary Ge
Chief Technology Officer
Dr. Gary Ge is a biotechnology innovator with 15+ years of experience uniting data science, AI, and computational biology to accelerate drug discovery. His leadership experience includes serving as VP of Quantitative Biology at Vor Biopharma, Director at QIAGEN Digital Insights, and Founding Executive and VP of Product Development at OmicSoft, following earlier scientific roles at Amgen and Merck.
Dr. Jacques Banchereau
Chief Scientific Officer
Dr. Jacques Banchereau is a pioneer in human immunology with 40+ years of experience. He was Director of Schering-Plough's Laboratory, the Founding Director of the Baylor Institute for Immunology Research, and Chief Science Officer of Roche Nutley, leading Virology & Immunology. He served as Director of Immunological Sciences at The Jackson Laboratory, and later was the CSO of ImmunAI. He has been a Professor of Immunology at the Universities of Lyon and Paris, and at Mount- Sinai and Yale Medical Schools. He has authored >500 papers, which have been cited >151,000 times.
Dr. Qiang Zhang
Senior VP & Head of Advanced AI Drug Design Group
Dr. Qiang Zhang has led AccSalus’s R&D efforts in structure-based drug design while dramatically increasing hit finding capabilities using advanced AI algorithms. Prior to AccSalus, Dr. Zhang spent 16 years at Boehringer Ingelheim as principal scientist in the drug discovery team. Dr. Zhang holds double Ph.D. degrees in Physics and Chemistry, and an M.Sc. in Computer Science.
Jaymes Holland, R.Ph.
Head of Clinical Operations
An oncology clinical research veteran with 30+ years of industry experience, Jaymes Holland has a proven history of securing successful NDA submissions for key drugs such as Gleevec, Tasigna, Exjade, Avastin and Cabometyx/Cometriq. He has held senior leadership positions at Novartis and Genentech. Jaymes was an Executive Director at Exelixis guiding trials from development through NDA approval for Cabometyx/Cometriq.Scientific Advisory Board
Dr. Edison Liu
Chairman of the Science Advisory Board
Dr. Edison Liu is an international expert in cancer biology, systems genomics, human genetics, molecular epidemiology and translational medicine with 35+ years of leadership experience in academia, and medicine. Previously, Dr Liu was the president and CEO of The Jackson Laboratory, founding executive director of the Genome Institute of Singapore, Chairman of the Board for Singapore’s FDA equivalent (HSA) and Scientific Director of the National Cancer Institute (USA).Currently, he is Professor and President Emeritus of The Jackson Laboratory. He has authored more than 350 scientific papers and reviews and co-authored two books.
Dr. Eyal Attar
Member of Science Advisory Board
Dr. Eyal Attar is a Harvard-trained, board certified hematologist and oncologist with over 25+ years of clinical, scientific and drug development experience. He was previously on the faculty and Massachusetts General Hospital and Harvard Medical School and has served as Chief Medical Officer for privately held and public biotechnology companies. Dr. Attar has a successful track record across drug development from discovery to INDs and NDAs, with experience developing small molecule, large molecule and cell therapy modalities.
Dr. Yan Yang
Chief Operating Officer & Member, SAB
Dr. Jacques Banchereau
Chief Scientific Officer & Member, SAB
Join the AccSalus Team
Be Part of The Medical Innovation
Transform Lives
Work on groundbreaking projects that aim to enhance patient care and improve treatment options.
Collaborative Environment
Collaborate with a diverse team of experts, where your ideas and contributions are valued.
Professional Growth
Enjoy opportunities for continuous learning and professional development to sharpen your skills and advance your career.
Shared Vision
Be part of a mission-focused culture, united in the goal of pushing the boundaries of medical science.